In one of the largest studies to date to use metabolomics, the study of compounds that are created through various chemical reactions in the body, researchers have been able to identify new circulating compounds associated with the risk of developing dementia and Alzheimer’s disease (AD).
The findings, which appear in the journal Alzheimer and Dementia, point to new biological pathways that may be implicated in AD and could serve as biomarkers for risk of the disease.
AD is the most common form of dementia responsible for a slow and progressive deterioration of memory and leads to frailty and dependence in elderly people.
